NCT04848337View on ClinicalTrials.gov

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

January 8, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer MetastaticNeuroendocrine Tumors
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.

DRUG

Lenvatinib

Lenvatinib 20 mg orally daily.

Trial Locations (5)

30322

Winship Cancer Instituted of Emory University, Atlanta

48109

University of Michigan Health System, Ann Arbor

53226

Froedtert and The Medical College of Wisconsin, Milwaukee

91010

City of Hope, Duarte

97239

Oregon health, Portland

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Hoosier Cancer Research Network

OTHER

lead

University of Michigan Rogel Cancer Center

OTHER